Barclays lowered the firm’s price target on Biogen to $200 from $215 and keeps an Equal Weight rating on the shares post the Q1 report. Skyclarys and Leqembi showed momentum, albeit against low expectations, while Spinraza’s outlook was ratcheted lower, the analyst tells investors in a research note. The firm says a GLP-1 overhang is looming for Biogen.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: